How can Shanghai's biomedical industry achieve the joint efforts of production, education and research?On December 14, The Paper (www.The reporter learned from a closed-door meeting in Zhangjiang, Shanghai to discuss the future industry-university-research cooperation of talents, and the cutting-edge synthetic biology research has seen the inevitability of the union of the biological community and engineers.
The future of synthetic biology is for the biology community and engineers to unite.
Deng Zixin, academician of the Chinese Academy of Sciences and academician of the American Academy of Microbiology, shared the disruptive innovation path of synthetic biotechnology and industrial development in the context of ecological civilization.
Deng Zixin said that the development of ecological civilization has given birth to a change in the business of synthetic biology, "This discipline is based on the development of sequencing technology, gene cloning technology and big data technology, using synthetic biology technology to edit various microorganisms and even human microorganisms." It can permeate our lives in all aspects of medical care, environment, health, energy, food, etc. ”
"The future of synthetic biology is for the biology community and engineers to join forces to rewire and program organisms, which will be able to produce cheaper medicines, foods and health products in the future," Deng said. ”
The biomedical industry needs both high-end talents and front-line workers.
Liu Houjia, director and branch secretary of Shanghai Biomedical Industry Promotion Center, shared the development trend of talents in Shanghai's biomedical industry in 2023.
In 2022, the scale of China's biopharmaceutical industry will be about 42 trillion yuan, a year-on-year increase of 58%；In 2022, the scale of Shanghai's biomedical industry will be about 853.7 billion yuan, a year-on-year increase of 121%；Growth is expected to continue in 2023. At present, there are about 280,000 employees in Shanghai's biomedical industry, of which a quarter are in ZhangjiangThe increase in master's and doctoral degrees is more obvious, and the number of bachelor's degree or above is 527%。
Liu Houjia believes that there is a gradient in the needs of enterprises to employ people, "not only need to have leading people, but also need front-line industrial workers". It said that from the perspective of the next 1-2 years, the shortage of talents in the innovative drug industry will continue to be in short supply. In the first half of 2023, among the mid-to-high-end job recruitments of enterprises, the number of pharmaceutical R&D positions is the largest. By the end of the "14th Five-Year Plan", the total demand for biomedical talents was 3680,000 to 4770,000 people, the talent gap is still large, especially high-level R&D talents. To this end, it is recommended that colleges and universities do some targeted training.
The Paper, for more original information, please **"The Paper" app).